RxSight, Inc. (RXST) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

10/25

Growth 1 Margin 2 Expansion 4 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
RxSight (RXST) Q2 2026: Core Sales Drop 20% as Competitive Trialing Hits Premium IOL Demand
July 07, 2026
7
RxSight (RXST) Q1 2026: LAL Mix Hits 88% of Revenue as Utilization Stabilizes
May 07, 2026
14
RxSight (RXST) Q4 2025: LAL Mix Hits 86% as LDD Sales Drop 64%, Shifting Margin Profile
February 26, 2026
16
RxSight (RXST) Q3 2025: LAL Mix Jumps to 85%, Resetting Margin Baseline
November 06, 2025
13
RxSight (RXST) Q2 2025: LDD Sales Drop 49% as Utilization Refocuses Growth Strategy
August 08, 2025
14
RxSight (RXST) Q1 2025: LAL Revenue Rises 37% as Macro and Competitive Friction Delays Recovery
July 04, 2025
RxSight (RXST) Q4 2024: LAL Procedure Volume Surges 61% as Adjustable IOL Adoption Expands
February 25, 2025
RxSight (RXST) Q3 2024: LDD Installed Base Jumps 51% as Premium IOL Adoption Deepens
November 09, 2024

Browse all companies